Scribe Therapeutics (NASDAQ:SCTX) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Scribe Therapeutics (NASDAQ:SCTX) to a hold rating in a research note issued to investors on Tuesday morning,Zacks reports.

Several other research analysts also recently weighed in on SCTX. HC Wainwright initiated coverage on shares of Scribe Therapeutics in a research note on Monday. They issued a “buy” rating and a $60.00 target price for the company. Guggenheim assumed coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $50.00 price target for the company. Wells Fargo & Company initiated coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 price objective for the company. Leerink Partners began coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 target price for the company. Finally, Wall Street Zen upgraded shares of Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.75.

Scribe Therapeutics Stock Performance

Shares of NASDAQ:SCTX opened at $30.90 on Tuesday. Scribe Therapeutics has a one year low of $17.31 and a one year high of $39.60.

Scribe Therapeutics (NASDAQ:SCTX) last released its quarterly earnings results on Wednesday, September 2nd. The company reported ($3.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.20) by $2.36. On average, equities research analysts expect that Scribe Therapeutics will post -6.72 earnings per share for the current year.

Insider Transactions at Scribe Therapeutics

In other Scribe Therapeutics news, Director Behzad Aghazadeh purchased 2,383,333 shares of the business’s stock in a transaction on Friday, July 24th. The stock was bought at an average cost of $15.15 per share, with a total value of $36,107,494.95. Following the acquisition, the director owned 3,080,983 shares of the company’s stock, valued at $46,676,892.45. The trade was a 341.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Bio Fund Ii L.P. Ah bought 333,333 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The shares were acquired at an average cost of $15.00 per share, with a total value of $4,999,995.00. Following the completion of the purchase, the insider owned 2,385,075 shares of the company’s stock, valued at approximately $35,776,125. The trade was a 16.25% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 3,727,237 shares of company stock worth $56,291,746.

Key Scribe Therapeutics News

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: Quarterly loss beat expectations: Scribe reported a second-quarter 2026 loss of $3.84 per share, significantly narrower than the $6.20 loss analysts expected. The earnings surprise may have improved sentiment toward the clinical-stage biotechnology company. Scribe Therapeutics earnings press release
• Positive Sentiment: Pipeline advanced into human testing: The company initiated the first-in-human Phase 1 trial of STX-1150, an ultra-long-acting LDL-cholesterol-lowering therapy using its ELXR epigenetic silencing technology. The treatment is designed to avoid permanent genetic changes, potentially strengthening Scribe’s cardiovascular disease pipeline. Scribe Therapeutics second-quarter results and corporate highlights
• Positive Sentiment: Non-dilutive support and financing improved runway: Scribe received more than $25 million from the California Institute for Regenerative Medicine to advance STX-1200 and STX-1400. In addition, its upsized IPO, including the underwriters’ full option exercise, and a private placement to Sanofi generated approximately $155.5 million in gross proceeds. Management said available funding should support operations into the first half of 2029. Scribe Therapeutics financing and financial results
• Positive Sentiment: Analyst coverage was bullish: HC Wainwright began coverage with a “Buy” rating and a $60 price target, well above the stock’s recent trading level. The firm projects continued losses but expects quarterly losses to narrow after 2026.
• Neutral Sentiment: Management also announced participation in upcoming investor conferences, which could provide additional visibility for Scribe’s technology and clinical programs but does not itself change the company’s fundamentals. Scribe Therapeutics investor conference announcement
• Negative Sentiment: Scribe remains unprofitable, with HC Wainwright forecasting a $6.72 per-share loss for fiscal 2026 and a $4.90 loss for fiscal 2027. Continued clinical spending and the recently issued equity could also create ongoing dilution and volatility risks.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.